VEGFA and neoplasm: Apatinib is an oral highly selective tyrosine kinase inhibitor that targets the VEGF receptor‐2, blocks the signal transduction by inhibiting the combination of VEGF and its receptor, and then suppresses tumor angiogenesis.8